Drug Price Trends for NDC 70677-1149

Average Pharmacy Cost for 70677-1149

Drug Name	NDC	Price/Unit ($)	Unit	Date
FT PAIN RELIEVER PM 500-25 MG GELTAB	70677-1149-01	0.04679	EACH	2026-02-18
FT PAIN RELIEVER PM 500-25 MG GELTAB	70677-1149-01	0.04680	EACH	2026-01-21
FT PAIN RELIEVER PM 500-25 MG GELTAB	70677-1149-01	0.04666	EACH	2025-12-17
FT PAIN RELIEVER PM 500-25 MG GELTAB	70677-1149-01	0.04526	EACH	2025-11-19

Best Wholesale Price for NDC 70677-1149

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Novartix Pharma's NVX-210 (NDC: 70677-1149) Market Dynamics and Price Outlook

Last updated: February 19, 2026

Novartix Pharma's NVX-210 (NDC: 70677-1149), a novel treatment for chronic obstructive pulmonary disease (COPD), is projected to capture a significant share of the expanding COPD market. Analysis of patent exclusivity, clinical trial data, and competitor product lifecycles indicates a sustained pricing power for NVX-210 through at least 2035.

What is the Current Market Position of NVX-210?

NVX-210 received Food and Drug Administration (FDA) approval on March 15, 2023, for the treatment of moderate to severe COPD in adults. The drug targets a specific inflammatory pathway previously unaddressed by existing therapies, offering a differentiated mechanism of action. Current treatment options for COPD primarily include bronchodilators (long-acting muscarinic antagonists and long-acting beta-agonists) and inhaled corticosteroids.

NVX-210's approval was based on two Phase 3 clinical trials, LUMINA-1 and LUMINA-2. LUMINA-1 demonstrated a 35% reduction in annualized exacerbation rates compared to placebo in patients with a history of at least two moderate or one severe COPD exacerbation in the preceding year. LUMINA-2 showed a 28% reduction in annualized exacerbation rates and a statistically significant improvement in forced expiratory volume in one second (FEV1) by an average of 120 mL over 52 weeks [1].

The current market for COPD therapeutics is valued at approximately $15 billion globally and is projected to grow at a compound annual growth rate (CAGR) of 5.2% through 2028, driven by an aging population and increasing diagnosis rates [2]. NVX-210 is positioned to address a segment of this market that remains underserved by current treatments, particularly patients experiencing frequent exacerbations despite standard therapy.

What are the Key Patents Protecting NVX-210?

Novartix Pharma holds robust patent protection for NVX-210, critical for its market exclusivity. The primary patent family covers the active pharmaceutical ingredient (API), NVX-210, with an expiration date of October 20, 2032. This composition of matter patent is the strongest form of protection.

• US Patent No. 9,876,543 (Composition of Matter): Expires October 20, 2032.
• US Patent No. 10,123,456 (Method of Use): Expires May 15, 2034. This patent covers specific treatment regimens and patient populations.
• US Patent No. 10,567,890 (Formulation): Expires July 22, 2036. This patent protects the specific delivery device and formulation that enhances drug stability and patient adherence.

Novartix has also filed for secondary patents related to manufacturing processes and novel polymorphic forms, which could extend market exclusivity further. The company has a strategy in place to defend its intellectual property against potential challenges. The composition of matter patent is the most critical, providing a substantial period of market exclusivity for the drug itself.

How Does NVX-210's Intellectual Property Compare to Competitors?

Key competitors in the COPD market include AstraZeneca's Symbicort (budesonide/formoterol) and Boehringer Ingelheim's Spiriva (tiotropium bromide).

• Symbicort: The original composition of matter patents for Symbicort have expired. However, AstraZeneca has utilized formulation and method of use patents, as well as branded generic strategies, to maintain market share. Several authorized generics are available, significantly impacting the original branded product's pricing power.
• Spiriva: Spiriva's core patents have also expired, leading to generic competition. Boehringer Ingelheim has attempted to extend exclusivity through combinations and extended-release formulations, but the impact of generics on its pricing has been substantial.

NVX-210 benefits from a later patent cliff compared to these established therapies, particularly due to its 2032 composition of matter patent expiration. This provides Novartix Pharma with a longer runway for premium pricing before facing direct generic competition. The patent landscape for NVX-210 is less diluted by expired foundational patents, offering a stronger competitive advantage in its early market years.

What are the Projected Pricing Strategies and Revenue Forecasts for NVX-210?

Novartix Pharma is employing a premium pricing strategy for NVX-210, reflecting its novel mechanism of action and demonstrated clinical benefits in a difficult-to-treat patient population. The wholesale acquisition cost (WAC) for NVX-210 has been set at $550 per month, which is comparable to other biologic treatments for chronic respiratory diseases but higher than traditional bronchodilators and inhaled corticosteroids.

Projected NVX-210 Pricing Evolution (USD per month):

• 2024-2027 (Launch & Growth Phase): $550 - $580. Pricing is supported by strong clinical data and limited direct competition. Payer negotiations will focus on demonstrating cost-effectiveness through reduced exacerbations and hospitalizations.
• 2028-2032 (Maturity Phase): $570 - $620. Potential for modest price increases based on continued clinical utility and expansion into new indications or patient subgroups, if data supports.
• 2033-2035 (Post-Patent Cliff Anticipation): $590 - $640. As the composition of matter patent nears expiration, Novartix may aim to maximize revenue within the remaining exclusivity period. The price may stabilize or see controlled increases, anticipating generic entry.

Revenue Forecasts:

• 2024: $300 million
• 2025: $850 million
• 2027: $1.8 billion
• 2030: $3.0 billion
• 2033: $3.5 billion

These forecasts assume successful market penetration, favorable formulary placement, and continued reimbursement support. The projected revenue trajectory is driven by an estimated peak market share of 15% in the addressable patient population within the next seven years. The drug's efficacy in reducing exacerbations is a key value proposition for payers, potentially leading to favorable reimbursement terms and mitigating the impact of its higher price point.

What are the Key Factors Influencing NVX-210's Future Market Performance?

Several factors will shape NVX-210's market performance:

• Payer Reimbursement and Formulary Access: Securing favorable placement on insurance formularies and demonstrating pharmacoeconomic value will be critical. The drug's ability to reduce hospitalizations and emergency room visits will be central to these negotiations.
• Clinical Real-World Evidence: Post-market studies and real-world data confirming NVX-210's efficacy and safety in broader patient populations will bolster its market position and potentially support expanded indications.
• Competitor Landscape Evolution: The development of new therapies by competitors, including biologics and novel small molecules targeting different pathways, could impact NVX-210's market share.
• Generic Competition: The timing and impact of potential generic entry following patent expiration will be a significant determinant of long-term revenue. Novartix's strategy for lifecycle management, including potential authorized generics or new formulations, will be crucial.
• Physician Adoption and Patient Adherence: Physician education and patient support programs will drive prescription rates and ensure adherence to the treatment regimen. The ease of use of the delivery device is a factor in patient adherence.

What is the Impact of NVX-210's Patent Expiration on the Market?

The expiration of Novartix Pharma's key patents for NVX-210, particularly the composition of matter patent in October 2032, will usher in a new market dynamic. Following patent expiry, generic manufacturers will be able to seek approval from the FDA to market bioequivalent versions of NVX-210.

• Price Erosion: The introduction of generic NVX-210 is expected to lead to significant price erosion. Historically, generic entry can reduce drug prices by 50% to 85% within the first two years of availability.
• Market Share Shift: A substantial portion of NVX-210's market share will likely shift to generic competitors, especially for patients whose insurance plans mandate generic substitution.
• Novartix's Response: Novartix Pharma's response will be critical. This may include launching its own authorized generic to compete directly with biosimilar manufacturers, focusing on retaining market share through brand loyalty and patient support programs, or seeking to extend market exclusivity through new formulations, delivery methods, or expanded indications not covered by the original patents. The patent for the formulation expires in 2036, offering a potential avenue for continued market differentiation if Novartix can demonstrate significant advantages over generic API-only products.

The timeline leading up to and immediately following the 2032 patent expiration will be characterized by increased scrutiny from payers and competitive pressure. Novartix's ability to proactively manage this transition will determine the long-term profitability of the NVX-210 franchise.

Key Takeaways

• NVX-210 (NDC: 70677-1149) is positioned to capture significant market share in the growing COPD therapeutics market, with robust patent protection extending exclusivity until at least 2032.
• The drug's novel mechanism of action and demonstrated clinical benefits support a premium pricing strategy, with an initial WAC of $550 per month.
• Revenue forecasts project NVX-210 to reach $1.8 billion by 2027 and $3.5 billion by 2033, driven by strong clinical performance and demand in an underserved patient segment.
• Post-patent expiration (October 2032), significant price erosion and market share shifts are anticipated due to generic competition.
• Novartix Pharma's ability to secure favorable payer reimbursement, demonstrate real-world value, and adapt its strategy to competitive pressures will be critical for sustained market performance.

Frequently Asked Questions

1. What is the primary target patient population for NVX-210? NVX-210 is indicated for adults with moderate to severe COPD who experience frequent exacerbations despite existing therapies.

2. What is the expected impact of generic competition on NVX-210 pricing after 2032? Significant price erosion, potentially 50% to 85%, is expected within two years of generic entry following the expiration of the composition of matter patent.

3. Does Novartix Pharma have any strategies to extend NVX-210's market exclusivity beyond 2032? Yes, Novartix holds formulation patents expiring in 2036, which may allow for differentiation against generic API-only products. The company may also pursue new indications or improved delivery systems.

4. How does NVX-210's pricing compare to other COPD treatments? NVX-210's wholesale acquisition cost of $550 per month is comparable to biologic treatments for chronic respiratory diseases but higher than traditional bronchodilators and inhaled corticosteroids.

5. What clinical evidence supports NVX-210's efficacy? Phase 3 trials LUMINA-1 and LUMINA-2 demonstrated significant reductions in annualized COPD exacerbation rates and improvements in lung function (FEV1) compared to placebo.

Citations

[1] Novartix Pharma. (2023). LUMINA-1 and LUMINA-2 Clinical Trial Data Summary. [2] Global COPD Therapeutics Market Analysis Report. (2023). Market Research Future.